Influenza vaccine one shot is hard to get: queuing up for appointment to compete for quality, and yellow cattle are sold with nearly three times the price increase

 Influenza vaccine one shot is hard to get: queuing up for appointment to compete for quality, and yellow cattle are sold with nearly three times the price increase

Yu Fei (pseudonym), who works in Dongcheng District of Beijing, recently wanted to make an appointment for influenza vaccination. A staff member from the health care department of Dongzhimen community service station in Beijing told Yu Fei that only 180 vaccines had been approved in September, and all had been finished, but more than 1000 people had made an appointment from September 23 to September 29. Yu Fei asked when he could make an appointment for influenza vaccine, and the staff said that no one can tell..

On September 29, Yu Fei called the outpatient number of Beijing Youan Hospital Affiliated to Capital Medical University in Fengtai District. The staff said that the appointment had been made to the end of November. The manufacturer of the first batch of influenza vaccine was Hualan biological, and the manufacturer of the second batch of vaccine was not clear. The staff suggested that Yu Fei could try in a private hospital.

Now you have Miao. You can make an appointment only after you pay. Please consult customer service for details. Yu Fei was excited by the response of staff from a private hospital in Beijing. However, from 1:00 to 5:00 p.m., the hospitals customer service telephone was always in the busy line state, which poured cold water on Yu Fei.

Zhongxin Jingwei reporter learned from the health care department of Hepingli community health service center that people who started to make an appointment for vaccination in October of last year began to make an appointment in September this year, this years arrangements are different from those in the past. The arrival quantity is less than the purchase quantity, and the time is also out of order..

Zhongxin Jingwei reporter randomly inquired about the health care department of Chaoyang Gate Community Health Service Center, Beijing Yuquan community health service station, Fengtai District Huaxiang community health service center, and wanwanwanzhuang community health service station. They were told that they could only line up with the equal number, and it was not clear when they could be on the line.

At present, we can only arrange tetravalent vaccines, and give priority to kindergartens at three prices, not to the outside world. Manufacturers and hospitals are also what arrangements, add money can not choose. Yellow cattle said that they arranged for their family members is Hualan biological influenza vaccine, after a week for friends arranged vaccination manufacturers, but only Jindike, no way, recently the vaccine is too tight, extremely short supply..

Screenshot of technical guidelines for influenza vaccination in China (2020-2021)

In addition to Beijing, according to public reports, there is a shortage of influenza vaccine in Shanghai, Tianjin, Chongqing, Wenzhou and other places. Under the tight supply and demand, vaccine prices also rise. Huang Niu told Yu Fei that the injection cost 398 yuan in October and 329 yuan in November.

However, people who have recently been vaccinated with influenza vaccine in Beijing community hospitals say that the price of a quadruple influenza vaccine is 128 yuan, while that of some community hospitals is 153 yuan. Compared with the price of community hospitals, the price of cattle is nearly three times that of ordinary vaccination. In addition, people in Guangzhou and Xiangtan, Hunan Province, introduced to the clients that the price of one influenza vaccine in local public hospitals was 69 yuan and 150 yuan respectively.

Is the listed company behind the influenza vaccine ready to expand its capacity?

Hualan biological Co., Ltd., mentioned by the staff of Beijing Youan Hospital Affiliated to Capital Medical University and cattle, is only one of the enterprises supplying influenza vaccine.

On September 29, a staff member surnamed Li from the Securities Department of Hualan Bio said in an interview with Zhongxin Jingwei reporter that Hualan biological has no plan to expand the production capacity of influenza vaccine at present, because the expansion of production capacity needs to expand the corresponding production line, but this is difficult to achieve in the short term.

As the enterprise with the largest market share of influenza vaccine products in China, Hualan biological Co., Ltd. accounted for 42% of the total number of influenza vaccines issued in 2019. Among them, Hualan biological vaccine Co., Ltd. accounted for 86.9% of the total number of tetravalent influenza vaccine batch issued in China.

Hualan biological influenza vaccine split vaccine. From Hualan biological official website

According to the annual report of 2019, a total of 12.9314 million influenza vaccines were approved and issued by Hualan biological vaccine Co., Ltd. (including 8.3593 million tetravalent influenza vaccines and 4.5721 million trivalent influenza vaccines). The operating revenue of the vaccine company was 1.049 billion yuan, an increase of 30.68% over the same period of last year, and the net profit was 375 million yuan, an increase of 38.92% over the same period of last year.

According to the information disclosed by China Academy of food and drug control, in addition to Hualan biological products, the enterprises supplying influenza vaccine this year include Changchun Institute of biological products, Dalian yalifeng biopharmaceutical Co., Ltd., Sanofi, Jiangsu Jindike biology and Beijing Kexing biological Co., Ltd. Among them, Dalian yalifeng is Fosun Pharmaceutical Co., Ltd., and Beijing Kexing biological Co., Ltd. is an unnamed pharmaceutical joint-stock company.

On September 29, Li Hongyu, deputy director of the chairmans office of Changchun hi tech, told Zhongxin Jingwei that from September 21 to September 27, Baike biological was approved to issue about 320000 influenza vaccines, totaling about 1.5 million. It is understood that Baike biological influenza vaccine will be put on the market in the second half of 2020, and the earliest batch will be approved and issued in mid and late August.

Influenza vaccine in short supply with 20% scrap rate

In fact, the market supply of influenza vaccine this year has increased significantly compared with previous years. Zhang Hui, vice president of China Academy of food and drug control, said on August 30, 2020 (the 37th Annual Meeting of national pharmaceutical industry information) that in 2019, a total of 30.7842 million bottles of influenza vaccine produced by six enterprises were issued, an increase of 90.6% compared with that in 2018.

At the same time, according to the statistics on the batch issuance of biological products released by the China Academy of food and drug control, as of September 8, the total number of influenza vaccine batches issued in China has exceeded 15.87 million, including 8.9427 million trivalent influenza vaccines, 4.0148 million tetravalent influenza vaccines and 2.9176 million lyophilized live attenuated influenza vaccines.

Why is influenza vaccine still hard to get? It seems difficult to get a single shot. In fact, many vaccines are ignored, leading to a 20% scrap rate of influenza vaccines in China. Tao Lina, a vaccine expert, said in an interview with the client of Zhongxin Jingwei.

In a research report published in mid September, Zou Kun, an analyst at Huaan securities, said that according to the number of influenza vaccine batches issued and the population in China, the vaccination rate of influenza vaccine in China is only about 2% - 3%, while that in developed countries is about 30% - 40%.

Tao Lina said the influenza vaccine is only valid for one year, the inventory can only be scrapped, and the hospital has to bear the cost of recycling and disposing of expired vaccines. The supply and demand of influenza vaccine is unbalanced, because the overall demand fluctuates greatly, and the demand varies greatly from place to place.

In the past years, why didnt you have a cold about influenza vaccine? Shi lichen, founder of Beijing Dingchen Management Consulting Co., Ltd., pointed out in an interview with Zhongxin Jingwei reporter that on the one hand, the viruses causing seasonal influenza epidemic are H1N1 and H3N2 subtypes of influenza A and Victoria and Yamagata strains of B virus. At present, the influenza vaccines approved for marketing in China include trivalent and tetravalent vaccine groups. Among them, trivalent influenza vaccine can prevent influenza A (H1N1), H3N2 (H3N2) and bv (type b), while the tetravalent influenza vaccine also contains by influenza virus immune antigen, so the preventive effect of influenza vaccine is relatively limited.

On the other hand, Shi lichen said that influenza vaccine belongs to the second category of voluntary and non compulsory vaccine, and residents pay for vaccination at their own expense. In peoples cognition, the cost of vaccination is far higher than that of taking cold medicine and anti-inflammatory medicine. The cost performance ratio of influenza vaccine is not high, and the market recognition of influenza vaccine is not high.

And the issuance of influenza vaccines has also brought about supply difficulties. According to the provisions of the vaccine administration law and relevant regulations, the vaccine marketing license holder shall supply the vaccine to the CDC according to the purchase contract, and then the CDC shall supply the vaccine to the vaccination unit according to the provisions. Units and individuals other than institutions for Disease Control and prevention shall not supply vaccines to vaccination units, nor shall vaccination units receive such vaccines.

This means that enterprises are unable to supply directly to vaccination units, there is a contradiction between the supply and demand of influenza vaccines in domestic provinces and cities, and they are unable to transfer goods from other places. As a result, vaccines in some places can not be used up and some places are not used up. Mr. Shi said.

Caitan is an in-depth financial research column jointly created by China Singapore Jingwei and Shenzhen Blue finance and economics. Sino Singapore Jingwei is a new financial media sponsored by China News Agency, which disseminates financial information, interprets economic policies and tells business stories. Deep blue finance, originated from the financial journalists community platform, is a new and cutting-edge financial and new media in China. It focuses on financial hot issues and deeply studies and analyzes the companys financial reports. (Zhongxin Jingwei APP)

Zhongxin Jingwei all rights reserved. No unit or individual is allowed to reprint, extract or use in any other way without written authorization.

(function(){( window.slotbydup=window .slotbydup||[]).push({id:u5811557,container:ssp_ 5811557, async:true }Source: China News Network Editor in charge: Kang Ruixin_ NB16727